Figure 7
Treatment with SP2509 and/or PS significantly enhances PS-mediated loss of viability of CD34+ primary AML cells and improves the survival of mice bearing AML xenografts and primagrafts. (b) Primary AML cells were treated with SP2509 and/or PS as indicated for 24 hours. Total cell lysates were prepared and immunoblot analyses were conducted for the expression levels of c-Myc, p21, p27, BIM, and β-actin in the lysates.
